Hemostasis Today

April, 2026
April 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
Bruno Pougault on the Limitations of DOACs in High-Risk Conditions
Nov 22, 2025, 16:17

Bruno Pougault on the Limitations of DOACs in High-Risk Conditions

Bruno Pougault, Global Marketing Hemostasis Product Manager at HORIBA, shared on LinkedIn:

DOACs may not be as efficacious or as safe as the current standard of care in conditions such as mechanical heart valves, thrombotic antiphospholipid syndrome, and atrial fibrillation associated with rheumatic heart disease”

Read the full article here.

Article: When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review

Authors: Antoine Bejjani, Candrika D. Khairani, Ali Assi, Gregory Piazza, Parham Sadeghipour, Azita H. Talasaz, John Fanikos, Jean M. Connors, Deborah M. Siegal, Geoffrey D. Barnes, Karlyn A. Martin, Dominick J. Angiolillo, Dawn Kleindorfer, Manuel Monreal, David Jimenez, Saskia Middeldorp, Mitchell S. V. Elkind, Christian T. Ruff, Samuel Z. Goldhaber, Harlan M. Krumholz, Roxana Mehran, Mary Cushman, John W. Eikelboom, Gregory Y. H. Lip, Jeffrey I. Weitz, Renato D. Lopes, Behnood Bikdeli

Bruno Pougault on the Limitations of DOACs in High-Risk Conditions

Stay updated on all scientific advances with Hemostasis Today.